Patents

US 10564159 B2: Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity

Granted
2020-02-18
Filed
2017-09-26 application 15715703
Type
Utility · 12 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. Such improvements are based upon the superior performance of assays comprising a chimeric TSH receptor in the presence of a glucocorticoid including, but not limited to, dexamethasone.

Source: PVGPATDIS, file of 2026-04-10 (ipg200218.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Diagnostic Hybrids, Inc. 13 patentsUS company or organizationAthens, OHDIAGNOSTIC HYBRIDS, INC. State business registration EXACT high confidence: identical full name and statePVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Leonard KohnWoodville, OH4PVGPATDIS, file of 2026-04-10
James L. BrownAthens, OH12PVGPATDIS, file of 2026-04-10
David R. SchollAthens, OH9Person page FUZZY medium confidencePVGPATDIS, file of 2026-04-10
Yunsheng LiAthens, OH14PVGPATDIS, file of 2026-04-10
Giorgio NapolitanoPescara, IT4PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
C12NMicroorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture mediaC12N5/0602PVGPATDIS, file of 2026-04-10
C07KPeptidesC07K14/72PVGPATDIS, file of 2026-04-10
G01NInvestigating or analysing materials by determining their chemical or physical propertiesG01N33/566PVGPATDIS, file of 2026-04-10
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms ; compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processesC12Q1/6883PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2022-05-31Release of security interest
Release of security interest
BANK OF AMERICA, N.A. signed 2022-05-27DIAGNOSTIC HYBRIDS, INC. ATHENS, OH60053/211ECORSEXC, file of 2026-09-25
2018-08-31Security interest Security interest
Security interest
DIAGNOSTIC HYBRIDS, INC. signed 2018-08-31BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT CHARLOTTE, NC46767/806ECORSEXC, file of 2026-09-25
2017-10-27Assignment
Assignment of assignor's interest
NAPOLITANO, GIORGIO signed 2009-07-21
BROWN, JIM signed 2009-07-27
LI, YUNSHENG signed 2009-07-27
SCHOLL, DAVID signed 2009-07-28
KOHN, LEONARD signed 2009-07-31
DIAGNOSTIC HYBRID, INC. ATHENS, OH43970/331ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.